1-Benzylimidazole attenuates the stemness of breast cancer cells through partially targeting CYP4Z1.
Hai QinYi ZhouHai LiuYaqin YuanQianqian GuoManqin YuanTao XiYujie ZhangPublished in: Environmental toxicology (2023)
Cytochrome P450 (CYP) 4Z1 (CYP4Z1) has recently garnered much interest as its expression predicts a poor prognosis and as a oncogene in breast cancer, and overexpressed in other many cancers. We previously showed that CYP4Z1 acts as a promoter of cancer stem cells (CSCs) to facilitate the occurrence and development of breast cancer. Here, RNA sequencing found that 1-benzylimidazole (1-Benzy) held a preferable correlation with breast cancer and suppressed the expression of CSC makers. Further functional experiments, including mammary spheroid formation, wound-healing, transwell-invasion, detection of tumor initiation, and metastatic ability, showed that 1-Benzy suppressed the stemness and metastasis of breast cancer cells. Additionally, we further demonstrated that CYP4Z1 is necessary for 1-Benzy-mediated suppression on breast cancer stemness and 1-Benzy exerted a weaker effect in breast cancer cells with CYP4Z1 knockdown. Taken together, our data suggest that 1-Benzy might be a potential drug suppressing breast cancer stemness via targeting CYP4Z1.
Keyphrases
- poor prognosis
- breast cancer cells
- cancer stem cells
- stem cells
- long non coding rna
- epithelial mesenchymal transition
- small cell lung cancer
- squamous cell carcinoma
- gene expression
- cancer therapy
- dna methylation
- machine learning
- risk assessment
- big data
- emergency department
- binding protein
- artificial intelligence
- single cell
- young adults
- drug induced
- climate change
- adverse drug
- loop mediated isothermal amplification